Navigation Links
Foamix Receives US Patent on Novel Foam Technology
Date:8/24/2009

NESS ZIONA, Israel, August 24 /PRNewswire/ -- Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

Dr. Dov Tamarkin, the Company's CEO stated, "The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has five issued U.S. patents covering its OilGel(TM) and topical foam technology platforms. An additional 70 U.S. patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices. The Company employs leading U.S. patent counsel (Wilmer Hale, Boston) as well as an in-house intellectual property team.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with 10 pharmaceutical and cosmetic companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an extensive in-house pipeline of dermatological and gynecological drugs in foam presentation.

Foamix holds 5 US patents and has 70 patents pending in the United States.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
4. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
5. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
8. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
9. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
10. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
11. REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... ... -Sciences division, Treximo will pair its $200M operational capacity with its strategic ... project management in areas affecting quality and operational management. With office ...
(Date:2/21/2017)... 2017  Lexus, a returning partner of the Amgen Tour ... exclusive automobile partner of the men,s and women,s events for the ... 2017 Amgen Tour of California will mark ... the best professional cycling teams in the world racing from Northern ... Amgen Breakaway from Heart Disease TM Women,s Race ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 12.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017 This ... Thousand by the following Product Types: Xylanase, Amylase, Cellulase, and ... Canada , Japan , ... Latin America , and Rest of World. ... Annual estimates and forecasts are provided for the ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):